2-methyl-N-{4-[(piperidin-4-ylamino)sulfonyl]-1-naphthyl}benzamide hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-methyl-N-{4-[(piperidin-4-ylamino)sulfonyl]-1-naphthyl}benzamide hydrochloride
• 英文别名: 2-methyl-N-[4-(piperidin-4-ylsulfamoyl)naphthalen-1-yl]benzamide;hydrochloride
• 化学式: C₂₃H₂₅N₃O₃S*ClH
• 分子量: 459.997
• InChiKey: MVYXVKZRGIMUBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.85
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  95.7
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-methyl-N-{4-[(piperidin-4-ylamino)sulfonyl]-1-naphthyl}benzamide hydrochloride 、 甲氧基乙酸 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 N-{4-[1-(2-methoxy-acetyl)-piperidin-4-ylsulfamoyl]-naphthalen-1-yl}-2-methyl-benzamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Naphthalene-Sulfonamide Antagonists of Human CCR8

  摘要：

  The design, synthesis, and structure-activity relationship development of naphthalene-derived human CCR8 antagonists is described. In vitro binding assay results of these investigations are reported, critical interactions of the antagonists with CCR8 are defined, and preliminary physicochemical and pharmacokinetic data for the naphthalene scaffold are presented.

  DOI：

  10.1021/jm061118e
• 作为产物：
  描述：

  4-[4-(2-methyl-benzoylamino)-naphthalene-1-sulfonylamino]-piperidine-1-carboxylic acid tert-butyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以5.0 g的产率得到2-methyl-N-{4-[(piperidin-4-ylamino)sulfonyl]-1-naphthyl}benzamide hydrochloride
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Naphthalene-Sulfonamide Antagonists of Human CCR8

  摘要：

  The design, synthesis, and structure-activity relationship development of naphthalene-derived human CCR8 antagonists is described. In vitro binding assay results of these investigations are reported, critical interactions of the antagonists with CCR8 are defined, and preliminary physicochemical and pharmacokinetic data for the naphthalene scaffold are presented.

  DOI：

  10.1021/jm061118e

文献信息

• [EN] CCR8 INHIBITORS<br/>[FR] INHIBITEURS DU CCR8
  申请人：MILLENNIUM PHARM INC

  公开号：WO2004058709A1

  公开（公告）日：2004-07-15

  Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

  揭示了由结构式（I）代表的CCR8抑制剂。结构式（I）中的变量在此处描述。还揭示了通过向受试者施用所披露的CCR8抑制剂之一来治疗CCR8介导的疾病，特别是哮喘的方法。
• Design, Synthesis, and Evaluation of Naphthalene-Sulfonamide Antagonists of Human CCR8
  作者：Tracy J. Jenkins、Bing Guan、Mingshi Dai、Gang Li、Thomas E. Lightburn、Shan Huang、B. Scott Freeze、Douglas F. Burdi、Swanee Jacutin-Porte、Robert Bennett、Weirong Chen、Charles Minor、Shomir Ghosh、Christopher Blackburn、Kenneth M. Gigstad、Matthew Jones、Roland Kolbeck、Wei Yin、Sean Smith、Daniel Cardillo、Timothy D. Ocain、Geraldine C. Harriman

  DOI：10.1021/jm061118e

  日期：2007.2.8

  The design, synthesis, and structure-activity relationship development of naphthalene-derived human CCR8 antagonists is described. In vitro binding assay results of these investigations are reported, critical interactions of the antagonists with CCR8 are defined, and preliminary physicochemical and pharmacokinetic data for the naphthalene scaffold are presented.